Unitaid
@unitaid.bsky.social
We save lives by making new health products available and affordable for people who need them most – fast. Hosted by WHO.
www.unitaid.org
www.unitaid.org
Saving more children’s lives won’t always mean inventing something new. It can mean making better use of what we already have.
Pulse oximetry can identify children needing urgent care, but only when linked to oxygen, referral and treatment.
https://ow.ly/l2zk50ZIckv
Pulse oximetry can identify children needing urgent care, but only when linked to oxygen, referral and treatment.
https://ow.ly/l2zk50ZIckv
September 14, 2026 at 6:00 PM
Saving more children’s lives won’t always mean inventing something new. It can mean making better use of what we already have.
Pulse oximetry can identify children needing urgent care, but only when linked to oxygen, referral and treatment.
https://ow.ly/l2zk50ZIckv
Pulse oximetry can identify children needing urgent care, but only when linked to oxygen, referral and treatment.
https://ow.ly/l2zk50ZIckv
Africa shouldn’t have to wait years for the next generation of HIV prevention.
Unitaid is supporting manufacturers in Uganda, Kenya and South Africa to prepare for potential future production of alimatravir, a once-monthly HIV prevention pill now in Phase 3 development.
https://ow.ly/gQNK50ZIakt
Unitaid is supporting manufacturers in Uganda, Kenya and South Africa to prepare for potential future production of alimatravir, a once-monthly HIV prevention pill now in Phase 3 development.
https://ow.ly/gQNK50ZIakt
September 4, 2026 at 2:50 PM
Africa shouldn’t have to wait years for the next generation of HIV prevention.
Unitaid is supporting manufacturers in Uganda, Kenya and South Africa to prepare for potential future production of alimatravir, a once-monthly HIV prevention pill now in Phase 3 development.
https://ow.ly/gQNK50ZIakt
Unitaid is supporting manufacturers in Uganda, Kenya and South Africa to prepare for potential future production of alimatravir, a once-monthly HIV prevention pill now in Phase 3 development.
https://ow.ly/gQNK50ZIakt
“The decisions countries make now will shape the impact these innovations can deliver.”
Unitaid is investing US$36M to build evidence for spatial emanators at scale and explore insecticide-treated baby wraps.
https://ow.ly/FbXW50ZI98Y
Unitaid is investing US$36M to build evidence for spatial emanators at scale and explore insecticide-treated baby wraps.
https://ow.ly/FbXW50ZI98Y
September 2, 2026 at 3:20 PM
“The decisions countries make now will shape the impact these innovations can deliver.”
Unitaid is investing US$36M to build evidence for spatial emanators at scale and explore insecticide-treated baby wraps.
https://ow.ly/FbXW50ZI98Y
Unitaid is investing US$36M to build evidence for spatial emanators at scale and explore insecticide-treated baby wraps.
https://ow.ly/FbXW50ZI98Y
20 years of progress. Millions of lives impacted. One mission: accelerating access to health innovations.
Hear from Unitaid's Executive Director, Philippe Duneton on our journey and what comes next.
Hear from Unitaid's Executive Director, Philippe Duneton on our journey and what comes next.
August 26, 2026 at 3:40 PM
20 years of progress. Millions of lives impacted. One mission: accelerating access to health innovations.
Hear from Unitaid's Executive Director, Philippe Duneton on our journey and what comes next.
Hear from Unitaid's Executive Director, Philippe Duneton on our journey and what comes next.
As lenacapavir becomes available in England, it remains out of reach for millions in LMICs.
The Independent and STOPAIDS look at what it will take to make this twice-yearly HIV prevention option accessible worldwide.
Unitaid is helping drive access.
https://ow.ly/fqn250ZEOL4
The Independent and STOPAIDS look at what it will take to make this twice-yearly HIV prevention option accessible worldwide.
Unitaid is helping drive access.
https://ow.ly/fqn250ZEOL4
August 25, 2026 at 6:00 AM
As lenacapavir becomes available in England, it remains out of reach for millions in LMICs.
The Independent and STOPAIDS look at what it will take to make this twice-yearly HIV prevention option accessible worldwide.
Unitaid is helping drive access.
https://ow.ly/fqn250ZEOL4
The Independent and STOPAIDS look at what it will take to make this twice-yearly HIV prevention option accessible worldwide.
Unitaid is helping drive access.
https://ow.ly/fqn250ZEOL4
Malaria remains one of the clearest examples of unequal progress in global health.
Africa accounts for 95% of deaths. A child still dies every minute.
Progress is real where access expands, but no single tool is enough.
Protection must be layered, sustained, and evolving.
#WorldMosquitoDay
Africa accounts for 95% of deaths. A child still dies every minute.
Progress is real where access expands, but no single tool is enough.
Protection must be layered, sustained, and evolving.
#WorldMosquitoDay
August 20, 2026 at 6:01 PM
Malaria remains one of the clearest examples of unequal progress in global health.
Africa accounts for 95% of deaths. A child still dies every minute.
Progress is real where access expands, but no single tool is enough.
Protection must be layered, sustained, and evolving.
#WorldMosquitoDay
Africa accounts for 95% of deaths. A child still dies every minute.
Progress is real where access expands, but no single tool is enough.
Protection must be layered, sustained, and evolving.
#WorldMosquitoDay
US$36m to generate evidence for scaling up new malaria prevention tools
Unitaid is funding projects led by Swiss TPH and CRID to generate evidence on spatial emanators and insecticide-treated baby wraps, helping inform country decisions and WHO guidance.
Unitaid is funding projects led by Swiss TPH and CRID to generate evidence on spatial emanators and insecticide-treated baby wraps, helping inform country decisions and WHO guidance.
August 18, 2026 at 6:01 PM
US$36m to generate evidence for scaling up new malaria prevention tools
Unitaid is funding projects led by Swiss TPH and CRID to generate evidence on spatial emanators and insecticide-treated baby wraps, helping inform country decisions and WHO guidance.
Unitaid is funding projects led by Swiss TPH and CRID to generate evidence on spatial emanators and insecticide-treated baby wraps, helping inform country decisions and WHO guidance.
Every minute, a child dies from malaria.
As we look ahead, we recognise the progress made, and the need to stay ahead of resistance.
No single intervention is enough. Layered approaches combining prevention, diagnosis and treatment are essential.
As we look ahead, we recognise the progress made, and the need to stay ahead of resistance.
No single intervention is enough. Layered approaches combining prevention, diagnosis and treatment are essential.
August 17, 2026 at 6:00 PM
Every minute, a child dies from malaria.
As we look ahead, we recognise the progress made, and the need to stay ahead of resistance.
No single intervention is enough. Layered approaches combining prevention, diagnosis and treatment are essential.
As we look ahead, we recognise the progress made, and the need to stay ahead of resistance.
No single intervention is enough. Layered approaches combining prevention, diagnosis and treatment are essential.
Africa is entering a new era of pharmaceutical manufacturing, but regionally made medicines depend on trust.
Bioequivalence provides evidence that generic medicines work just as safely and effectively as those already on the market.
Bioequivalence provides evidence that generic medicines work just as safely and effectively as those already on the market.
August 12, 2026 at 3:45 PM
Africa is entering a new era of pharmaceutical manufacturing, but regionally made medicines depend on trust.
Bioequivalence provides evidence that generic medicines work just as safely and effectively as those already on the market.
Bioequivalence provides evidence that generic medicines work just as safely and effectively as those already on the market.
For malaria innovations, speed matters.
The pathway from evidence to access for next-generation mosquito nets was reduced from 9 years to 3 years by aligning research, supply and procurement earlier.
Faster access helps communities benefit sooner.
The pathway from evidence to access for next-generation mosquito nets was reduced from 9 years to 3 years by aligning research, supply and procurement earlier.
Faster access helps communities benefit sooner.
August 11, 2026 at 6:00 PM
For malaria innovations, speed matters.
The pathway from evidence to access for next-generation mosquito nets was reduced from 9 years to 3 years by aligning research, supply and procurement earlier.
Faster access helps communities benefit sooner.
The pathway from evidence to access for next-generation mosquito nets was reduced from 9 years to 3 years by aligning research, supply and procurement earlier.
Faster access helps communities benefit sooner.
For frontline health workers, every moment matters.
In Kenya, Dr. Maureen Muchela shares how access to respiratory support is changing what is possible for premature and critically ill newborns.
In Kenya, Dr. Maureen Muchela shares how access to respiratory support is changing what is possible for premature and critically ill newborns.
August 10, 2026 at 6:00 AM
For frontline health workers, every moment matters.
In Kenya, Dr. Maureen Muchela shares how access to respiratory support is changing what is possible for premature and critically ill newborns.
In Kenya, Dr. Maureen Muchela shares how access to respiratory support is changing what is possible for premature and critically ill newborns.
From prototype to scale.
With support from Unitaid, Vayu’s bCPAP system moved from hand-built prototypes to a solution used in newborn care across Africa, Asia and Latin America.
500,000+ newborns and infants have now been treated globally.
With support from Unitaid, Vayu’s bCPAP system moved from hand-built prototypes to a solution used in newborn care across Africa, Asia and Latin America.
500,000+ newborns and infants have now been treated globally.
August 6, 2026 at 12:01 PM
From prototype to scale.
With support from Unitaid, Vayu’s bCPAP system moved from hand-built prototypes to a solution used in newborn care across Africa, Asia and Latin America.
500,000+ newborns and infants have now been treated globally.
With support from Unitaid, Vayu’s bCPAP system moved from hand-built prototypes to a solution used in newborn care across Africa, Asia and Latin America.
500,000+ newborns and infants have now been treated globally.
What does it take to turn innovation into equitable access?
That was the conversation at our #AIDS2026 satellite session marking 20 years of Unitaid. It was a privilege to hear from longstanding partners who have helped shape our journey – and to look ahead at what comes next.
That was the conversation at our #AIDS2026 satellite session marking 20 years of Unitaid. It was a privilege to hear from longstanding partners who have helped shape our journey – and to look ahead at what comes next.
July 28, 2026 at 7:10 PM
What does it take to turn innovation into equitable access?
That was the conversation at our #AIDS2026 satellite session marking 20 years of Unitaid. It was a privilege to hear from longstanding partners who have helped shape our journey – and to look ahead at what comes next.
That was the conversation at our #AIDS2026 satellite session marking 20 years of Unitaid. It was a privilege to hear from longstanding partners who have helped shape our journey – and to look ahead at what comes next.
Viral hepatitis claims 1.3 million lives every year.
The tools exist. The challenge is access.
Unitaid is supporting innovations that help make hepatitis prevention, testing and treatment simpler and more accessible.
#WorldHepatitisDay
The tools exist. The challenge is access.
Unitaid is supporting innovations that help make hepatitis prevention, testing and treatment simpler and more accessible.
#WorldHepatitisDay
July 28, 2026 at 6:15 AM
Viral hepatitis claims 1.3 million lives every year.
The tools exist. The challenge is access.
Unitaid is supporting innovations that help make hepatitis prevention, testing and treatment simpler and more accessible.
#WorldHepatitisDay
The tools exist. The challenge is access.
Unitaid is supporting innovations that help make hepatitis prevention, testing and treatment simpler and more accessible.
#WorldHepatitisDay
A cure for hepatitis C exists. The next challenge is making sure care reaches everyone who needs it.
A Unitaid-backed study led by Médecins du Monde in Armenia, Georgia and Tanzania is exploring how simpler approaches can accelerate access to hepatitis C treatment.
Read more below.
A Unitaid-backed study led by Médecins du Monde in Armenia, Georgia and Tanzania is exploring how simpler approaches can accelerate access to hepatitis C treatment.
Read more below.
July 27, 2026 at 9:15 AM
A cure for hepatitis C exists. The next challenge is making sure care reaches everyone who needs it.
A Unitaid-backed study led by Médecins du Monde in Armenia, Georgia and Tanzania is exploring how simpler approaches can accelerate access to hepatitis C treatment.
Read more below.
A Unitaid-backed study led by Médecins du Monde in Armenia, Georgia and Tanzania is exploring how simpler approaches can accelerate access to hepatitis C treatment.
Read more below.
Latin America & the Caribbean helped shape the future of HIV prevention. But will they benefit from the innovations they helped advance?
The region accounts for 1 in 10 new HIV infections globally, yet access to new innovations remains uneven.
#AIDS2026.
IAS - the International AIDS Society
The region accounts for 1 in 10 new HIV infections globally, yet access to new innovations remains uneven.
#AIDS2026.
IAS - the International AIDS Society
July 26, 2026 at 7:36 PM
Latin America & the Caribbean helped shape the future of HIV prevention. But will they benefit from the innovations they helped advance?
The region accounts for 1 in 10 new HIV infections globally, yet access to new innovations remains uneven.
#AIDS2026.
IAS - the International AIDS Society
The region accounts for 1 in 10 new HIV infections globally, yet access to new innovations remains uneven.
#AIDS2026.
IAS - the International AIDS Society
Innovation creates possibility. Preparation creates access.
We're investing now to help African manufacturers prepare for the potential future production of investigational once-monthly HIV prevention pill alimatravir (MK-8527), pending successful trials and regulatory approval.
We're investing now to help African manufacturers prepare for the potential future production of investigational once-monthly HIV prevention pill alimatravir (MK-8527), pending successful trials and regulatory approval.
July 24, 2026 at 3:46 PM
Innovation creates possibility. Preparation creates access.
We're investing now to help African manufacturers prepare for the potential future production of investigational once-monthly HIV prevention pill alimatravir (MK-8527), pending successful trials and regulatory approval.
We're investing now to help African manufacturers prepare for the potential future production of investigational once-monthly HIV prevention pill alimatravir (MK-8527), pending successful trials and regulatory approval.
#RethinkRebuildRise.
The HIV response has transformed what is possible, but progress is not reaching everyone equally.
At #AIDS2026, we’ll join the global community to discuss how innovation, partnership and access can shape the next chapter of the response.
Find us: https://ow.ly/F8L350ZqH0k
The HIV response has transformed what is possible, but progress is not reaching everyone equally.
At #AIDS2026, we’ll join the global community to discuss how innovation, partnership and access can shape the next chapter of the response.
Find us: https://ow.ly/F8L350ZqH0k
July 24, 2026 at 10:45 AM
#RethinkRebuildRise.
The HIV response has transformed what is possible, but progress is not reaching everyone equally.
At #AIDS2026, we’ll join the global community to discuss how innovation, partnership and access can shape the next chapter of the response.
Find us: https://ow.ly/F8L350ZqH0k
The HIV response has transformed what is possible, but progress is not reaching everyone equally.
At #AIDS2026, we’ll join the global community to discuss how innovation, partnership and access can shape the next chapter of the response.
Find us: https://ow.ly/F8L350ZqH0k
20 years.
150+ health products.
300 million people reached annually.
US$10 billion in projected savings by 2030.
Nearly 1 million additional lives saved.
The next 20 years start now.
150+ health products.
300 million people reached annually.
US$10 billion in projected savings by 2030.
Nearly 1 million additional lives saved.
The next 20 years start now.
July 24, 2026 at 7:15 AM
20 years.
150+ health products.
300 million people reached annually.
US$10 billion in projected savings by 2030.
Nearly 1 million additional lives saved.
The next 20 years start now.
150+ health products.
300 million people reached annually.
US$10 billion in projected savings by 2030.
Nearly 1 million additional lives saved.
The next 20 years start now.
Scientific breakthroughs only save lives when they reach communities. Ahead of #AIDS2026, we're investing an additional US$15M to support Global South-led partnerships and help countries prepare for the next generation of HIV prevention.
July 23, 2026 at 6:01 PM
Scientific breakthroughs only save lives when they reach communities. Ahead of #AIDS2026, we're investing an additional US$15M to support Global South-led partnerships and help countries prepare for the next generation of HIV prevention.
Behind every health innovation is a human story.
For 20 years, access to better medicines, diagnostics and prevention tools has helped change lives around the world.
For 20 years, access to better medicines, diagnostics and prevention tools has helped change lives around the world.
July 23, 2026 at 7:15 AM
Behind every health innovation is a human story.
For 20 years, access to better medicines, diagnostics and prevention tools has helped change lives around the world.
For 20 years, access to better medicines, diagnostics and prevention tools has helped change lives around the world.
Children living with HIV were once treated with medicines designed for adults.
Improving access meant creating treatments designed around children’s needs.
Because everyone deserves medicines that work for them.
#AIDS2026
Improving access meant creating treatments designed around children’s needs.
Because everyone deserves medicines that work for them.
#AIDS2026
July 22, 2026 at 3:15 PM
Children living with HIV were once treated with medicines designed for adults.
Improving access meant creating treatments designed around children’s needs.
Because everyone deserves medicines that work for them.
#AIDS2026
Improving access meant creating treatments designed around children’s needs.
Because everyone deserves medicines that work for them.
#AIDS2026
What does oil have to do with HIV medicines? More than you might think.
Our latest analysis reveals a hidden vulnerability in pharmaceutical supply chains: oil price shocks could increase the cost of producing first-line HIV treatment by up to 44%.
Explore the findings.
https://ow.ly/u7lY50ZrmCZ
Our latest analysis reveals a hidden vulnerability in pharmaceutical supply chains: oil price shocks could increase the cost of producing first-line HIV treatment by up to 44%.
Explore the findings.
https://ow.ly/u7lY50ZrmCZ
July 22, 2026 at 1:58 PM
What does oil have to do with HIV medicines? More than you might think.
Our latest analysis reveals a hidden vulnerability in pharmaceutical supply chains: oil price shocks could increase the cost of producing first-line HIV treatment by up to 44%.
Explore the findings.
https://ow.ly/u7lY50ZrmCZ
Our latest analysis reveals a hidden vulnerability in pharmaceutical supply chains: oil price shocks could increase the cost of producing first-line HIV treatment by up to 44%.
Explore the findings.
https://ow.ly/u7lY50ZrmCZ
Resistance doesn't wait.
To sustain progress against malaria and other diseases, innovation must move faster than the threats we face.
Protecting gains requires constant vigilance and continued investment.
To sustain progress against malaria and other diseases, innovation must move faster than the threats we face.
Protecting gains requires constant vigilance and continued investment.
July 22, 2026 at 10:15 AM
Resistance doesn't wait.
To sustain progress against malaria and other diseases, innovation must move faster than the threats we face.
Protecting gains requires constant vigilance and continued investment.
To sustain progress against malaria and other diseases, innovation must move faster than the threats we face.
Protecting gains requires constant vigilance and continued investment.